The current practices for new excipient approval by regulatory agencies are grossly inefficient and hinder innovation. As many drugs’ patents expire, the excipient market is growing, and yet excipients lack independent approval processes separate from the drug. Natalie Healey asks Dr Chris Moreton from IPEC Americas what changes are necessary, and he discusses how investment in novel excipients may solve drug delivery challenges in future.

http://www.worldpharmaceuticals.net/features/featurea-bitter-pill-to-swallow-the-excipient-approval-process-4439976/